Related Experiment Videos
Glycoprotein IIb/IIIa Receptor Inhibitors During Primary Angioplasty for Acute Myocardial Infarction.
1Cardiovascular Research Foundation, Washington Hospital Center, Suite 4B-1, 110 Irving Street, NW, Washington, DC 20010, USA.
Current Interventional Cardiology Reports
|November 30, 2000
Summary
Platelet glycoprotein IIb/IIIa receptor antagonists effectively treat acute myocardial infarction (AMI) by preventing platelet aggregation. Intravenous abciximab shows promise in reducing thrombosis when combined with reperfusion therapy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Platelet glycoprotein IIb/IIIa receptors are crucial in platelet aggregation and coronary thrombosis during acute myocardial infarction (AMI).
- These receptors represent a key target for pharmacologic intervention in cardiovascular diseases.
Purpose of the Study:
- To review existing trials on the safety and efficacy of intravenous abciximab in AMI patients.
- To discuss ongoing studies evaluating the long-term benefits of combining abciximab with stenting for AMI treatment.
Main Methods:
- Review of six published clinical trials on intravenous abciximab as an adjunct to primary mechanical reperfusion in AMI.
- Analysis of current research investigating combined pharmacologic therapy and stenting.
Main Results:
- Glycoprotein IIb/IIIa receptor antagonists have demonstrated benefits and efficacy in acute coronary syndromes and percutaneous interventions.
- Intravenous abciximab has been evaluated in multiple trials for its safety and efficacy in AMI.
Conclusions:
- Glycoprotein IIb/IIIa receptor antagonists are effective in managing AMI and related thrombotic events.
- Further research is ongoing to establish the long-term advantages of combining abciximab with stenting in AMI management.